FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP


OMB APPROVAL 3235-0287 Estimated average burden

0.5

hours per response:

	Check this box if no longer subject to
٦	Section 16. Form 4 or Form 5
)	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Sawhney Amarpreet					2. Issuer Name and Ticker or Trading Symbol OCULAR THERAPEUTIX, INC [ OCUL ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director X 10% Owner					
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)							X Officer below)	(give title		Other (s below)	pecify		
C/O OCULAR THERAPEUTIX, INC.				0	02/04/2015							President and CEO						
36 CROS	SBY DRIVI	E, SUITE 101																
				—   4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) BEDFORD MA 01730											X Form fil							
				_									Form fil Person	ed by More	e than	One Report	ing	
(City)	(S	tate)	(Zip)										1 013011					
		Ta	ble I - Non-D	erivati	ve Se	curities	s Ac	quired, [	Disp	osed o	f, or Be	neficiall	y Owned					
Date				2A. Deemed Execution Date, if any (Month/Day/Yea		e, Transaction Disposed O Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amour Securities Beneficia Owned For	s Form ally (D) o ollowing (I) (Ir		: Direct     	7. Nature of ndirect Beneficial Ownership				
								Code	v	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a	ion(s)			Instr. 4)	
			Table II - Der (e.g					uired, Di , options	•			•	Owned					
Derivative Conversion Dat		3. Transaction Date (Month/Day/Year)  3. Deemed Execution Dat if any (Month/Day/Year)		Code (Instr.		Derivative I		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		piration ate	Title	Amount or Number of Shares		(Instr. 4)	on(s)			
Stock Option (Right to Buy)	\$30.07	02/04/2015		A		170,000		(1)	02	2/03/2025	Common Stock	170,000	\$0.00	170,00	00	D		

## **Explanation of Responses:**

 $1. \ Vests \ over four \ years, \ vesting \ 1/48 \ monthly \ beginning \ on \ the \ one-month \ anniversary \ of \ the \ date \ of \ grant.$ 

## Remarks:

/s/ W. Bradford Smith, as Attorney-in-Fact for Amarpreet 02/05/2015 Sawhney

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.